Patent intelligence · US
US 9457075
Modified foot and mouth disease virus (FMDV) VP1 capsid protein
Modified foot and mouth disease virus (FMDV) VP1 capsid protein
Patent details — US 9457075
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 4, 2016
- Expiration
- Sep 29, 2036
- Applicant
- The Pirbright Institute
- Claims
- 8
- CPC classes
- A61K, A61K39/135
Quick answer
US 9457075 (Modified foot and mouth disease virus (FMDV) VP1 capsid protein) is held by The Pirbright Institute. Status: granted. Granted Oct 4, 2016. Expires Sep 29, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- The Pirbright Institute
- Grant date
- Expiration
- Claims
- 8
- CPC classes
- A61K, A61K39/135
More from The Pirbright Institute
Related pharmaceutical patents in our USPTO index.
-
US 12383631
Immune antigen specific IL-18 immunocytokines and uses thereof
granted -
US 12350120
Gum-protecting and teeth-whitening strip and preparation method thereof
granted -
US 12220447
Proteolytic enzyme composition
granted -
US 12215133
GIP and GLP-1 dual receptor agonist, pharmaceutical composition, and use
granted -
US 12173062
Modified TNF-α antibodies and uses thereof
granted -
US 12115136
Fortified CBD oil for treatment of PTSD
granted -
US 12097230
Method and composition for treating post operative conditions
granted -
US 11925686
Materials for phototherapies of ophthalmic diseases
granted
Frequently asked questions
What is US patent 9457075?
US 9457075 (Modified foot and mouth disease virus (FMDV) VP1 capsid protein) is held by The Pirbright Institute. Status: granted. Granted Oct 4, 2016. Expires Sep 29, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9457075?
The Pirbright Institute is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 57 pharmaceutical patents for this assignee.
When does US 9457075 expire?
Our index shows an expiration date of Sep 29, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.